Treatment of preeclamptic vessels with pravastatin enhances vessel function and alters caveolae form and distribution through removal of cellular cholesterol

Preeclampsia (PE) causes significant maternal and foetal morbidity and mortality. Maternal vascular endothelial dysfunction contributes to PE resulting in systemic organ dysfunction. Symptoms of PE are most effectively alleviated/managed through pre-term delivery and/or expectant care, highlighting the need for effective therapies to be identified. The potential clinical applications of pravastatin in the treatment of PE has been reported across multiple studies, however the mechanism(s) behind this is have yet to be elucidated.